Inhibrx Biosciences, Inc. (INBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.23B
Last updated: Nov 17, 2026 at 11:05 AM ET
Inhibrx Biosciences, Inc. (INBX) Stock Forecast
Analysts expect Inhibrx Biosciences (INBX) to earn -$9.26 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 3 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 75.0% |
| Hold | 1 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$9.26
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$8.76
- EPS consensus, revenue $36.05M
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$9.26 | -$9.58 to -$8.93 | 2 | N/A | N/A | 3 |
| Dec 31, 2027 | -$8.76 | -$9.05 to -$8.47 | 2 | $36.05M | $23.90M to $54.05M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.84 | -$3.46 to -$2.42 | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$9.26 | -$9.26 | -$9.26 | -$9.26 | -$9.26 | N/A |
| Fiscal year ending Dec 31, 2027 | -$8.76 | -$8.76 | -$8.76 | -$8.76 | -$6.30 | N/A |
Frequently Asked Questions About INBX
What is the INBX stock forecast?
Consensus analyst estimates put Inhibrx Biosciences's EPS at -$9.26 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.
How do analysts rate INBX stock?
Of 4 analysts covering Inhibrx Biosciences, 0 rate it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INBX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$9.26, with estimates from -$9.58 to -$8.93 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.76, with estimates from -$9.05 to -$8.47 from 2 analysts.
What revenue do analysts expect from Inhibrx Biosciences next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $36.05M, with estimates from $23.90M to $54.05M.
How many analysts cover INBX?
4 analysts rate Inhibrx Biosciences stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INBX pages: Overview, Earnings, Forecast, Financials, Competitors